July 31, 2018 / 7:27 PM / in 16 days

FDA approves blood disorder drug made by Japan's Shionogi

(Reuters) - The U.S. Food and Drug Administration on Tuesday approved Japan-based Shionogi & Co Ltd’s treatment for low blood-platelet count or thrombocytopenia in patients with chronic liver disease.

The treatment belongs to a new class of drugs called thrombopoietin receptor agonists (TPO RA), which stimulate platelet production. bit.ly/2LJJZPG

Its approval is the second for this class of drug for liver disease patients, following the FDA’s greenlight for U.S.-based Dova Pharmaceuticals’ rival treatment in May.

Reporting by Manas Mishra in Bengaluru

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below